天洋新材(603330.SH):HJT光轉膜產品已完成內部測試
格隆匯5月29日丨天洋新材(603330.SH)在業績説明會上表示,目前LECO激光燒結技術電池片已經量產,一些頭部組件廠商已經應用。天洋適用LECO電池的低酸EVA產品已經通過測試,並實現批量供貨。天洋的技術研發團隊一直保持對光伏產業新技術、新設備、新產品的關注和研究,自2023年開始就已經佈局低酸EVA膠膜產品的研發和技術儲備,依託天洋20多年高分子合成和改性經驗,截止目前,公司的EVA透明膜、白膜、共擠白膜、EPE膜、POE膜、低酸EVA膜(適用LECO)、承載膜(適用OBB)等產品已經全部實現量產供貨,HJT光轉膜產品已完成內部測試,後續將根據客户需求按需供貨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.